Chewed Versus Integral Pill of Ticagrelor in All Patients Undergoing Percutaneous Coronary intervention--a Platelet Reactivity and Patient Outcomes Study.
Phase of Trial: Phase IV
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Aurora Advanced Healthcare
- 15 Apr 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 10 Apr 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Dec 2019.
- 25 Oct 2018 New trial record